|
|
| Unaudited Quarterly Results for the First Quarter ended June 30, 2007 |
|
|
Stand alone |
Consolidated |
|
First Quarter Ended |
Year Ended |
First Quarter Ended |
Year ended |
Particulars |
30.06.2007 |
30.06.2006 |
31.03.2007 |
30.06.2007 |
31.03.2007 |
|
(Unaudited) |
(Unaudited) |
(Audited) |
(Unaudited) |
(Audited) |
| Sales/Income from Operations(including excise duty) |
5,086.8 |
4,385.6 |
19,797.2 |
5,664.4 |
22,502.2 |
| Less: Excise Duty |
287.3 |
244.2 |
1,011.5 |
341.0 |
1,273.0 |
| Net Sales/Income from Operations |
4,799.5 |
4,141.4 |
18,785.7 |
5,323.4 |
21,229.2 |
| Other Income |
329.6 |
60.3 |
431.3 |
335.3 |
496.3 |
| Total Income |
5,129.1 |
4,201.7 |
19,217.0 |
5,658.7 |
21,725.5 |
| Expenditure |
|
|
|
|
|
| a. (Increase) / Decrease in Stock in Trade |
(345.3) |
(445.1) |
(744.2) |
(439.6) |
(890.5) |
| b. Consumption of Raw Materials |
3,285.1 |
3,000.9 |
12,404.4 |
3,367.2 |
13,106.8 |
| c. Staff Cost |
336.6 |
258.0 |
1,128.8 |
442.3 |
1,504.2 |
| d. Other Expenditure |
984.0 |
668.8 |
3,210.7 |
1,258.7 |
4,490.0 |
| Total expenditure |
4,260.4 |
3,482.6 |
15,999.7 |
4,628.6 |
18,210.5 |
| Profit Before Depreciation, Interest & Tax |
868.7 |
719.1 |
3,217.3 |
1,030.1 |
3,515.0 |
| Interest (net) |
44.4 |
70.1 |
187.3 |
106.3 |
453.6 |
| Depreciation /Amortisation |
173.7 |
142.8 |
718.4 |
233.5 |
997.1 |
| Profit before taxation |
650.6 |
506.2 |
2,311.6 |
690.3 |
2,064.3 |
| Provision for Taxation |
|
|
|
|
|
| a. Current Tax (MAT Provision) |
75.7 |
58.1 |
180.5 |
80.6 |
203.4 |
| b. MAT Credit Entitlement |
(3.8) |
(52.2) |
(145.4) |
(3.8) |
(145.4) |
| c. Deferred Tax |
(7.7) |
137.4 |
(40.6) |
(7.7) |
(40.6) |
| d. Fringe Benefit Tax |
1.0 |
0.8 |
3.9 |
1.0 |
3.9 |
| e. Tax adjustments of previous years |
- |
- |
22.4 |
- |
22.4 |
| Total Tax |
65.2 |
144.1 |
20.8 |
70.1 |
43.7 |
| Profit before Minority Interest |
585.4 |
362.1 |
2,290.8 |
620.2 |
2,020.6 |
| Minority Interest |
|
|
|
(2.9) |
(11.0) |
| Net Profit |
585.4 |
362.1 |
2,290.8 |
617.3 |
2,009.6 |
| Paid-up Equity Share Capital |
|
266.3 |
266.7 |
|
266.7 |
| (Face value Rs. 5 per share) |
|
|
|
|
|
| Reserves excluding Revaluation Reserves |
|
|
9,020.6 |
|
8,587.5 |
| Basic Earnings per share (Rs.) (not annualised) |
10.97 |
6.80 |
42.98 |
11.57 |
37.70 |
| Diluted Earnings per share (Rs.) (not annualised) |
8.66 |
5.73 |
34.51 |
9.13 |
30.27 |
| Aggregate of Non-promoters Shareholding |
|
|
|
|
|
| a. Number of Shares |
|
|
23,636,405 |
|
|
| b. Percentage of Shareholding |
|
|
44.31 |
|
|
|
|
|
| Notes: |
| 1. |
The above unaudited results were reviewed by the Audit Committee and have been taken on record by the Board at its meeting held on 31.07.2007. The quarterly stand alone results are subject to Limited Review by Auditors of the Company. |
| 2. |
The Consolidated Quarterly Results, which are optional, have been presented for the first time by the Company, so as to provide additional information; and consequently no comparative figures of corresponding quarter of previous year is given. |
| 3. |
The consolidated Quarterly Results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement', AS-27 ' Financial Reporting of Interests in Joint Ventures' and includes Quarterly Results of all subsidiaries and 50:50 Joint Ventures. |
| 4. |
The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'. |
| 5. |
Investor complaintspending at the beginning of the quarter: Nil, received:52, resolved: 52 and Nil lying unresolved the end of the quarter. |
| 6. |
Sales for the quarter include exports of Rs.2772 millions (Rs.2515.9 millions). |
| 7. |
The Committee of Board of Directors of the Company on 11th July, 2007 has considered the request and allotted 3,74,046 Equity Shares of Rs. 5 Equity Shares of Rs.5 each for cash at a premium of Rs. 517.036 by conversion of Foreign Currency Convertible Bonds worth USD 4.5 Million (out of USD 60 Million) in terms of the offer document to the FCCB holders. |
| 8. |
Premium on redemption of USD 260 Million zero coupon Foreign Currency Convertible Bonds is contingent in nature, the outcome of which is dependant on uncertain future events. |
| 9. |
The Compensation Committee of the Company at their meeting held on 31st July, 2007 allotted 16,638 Equity Shares of Rs. 5 premium each at a premium of Rs.357.60 per share under ESOP 2004 Scheme. |
| 10. |
During the quarter, the Company has added new subsidiaries viz., Aurobindo Pharma Japan KK, Aurobindo Pharma Produtos Farmaceuticos Limitada, Brazil and Aurobindo Shanghai Trading Co. Ltd. |
| 11. |
Figures for the previous periods have been rearranged/regrouped wherever necessary. |
|
|
|
|
For and on behalf of the Board |
|
|
Sd/- |
| Place: Hyderabad |
|
K.Nityananda Reddy |
| Date : 31.07.2007 |
|
Managing Director |
|
|
|
